Senti Biosciences Holdings, Inc. (SNTI): Total Assets
$51.22M
As of 2025-12-31
$33.10M
As of 2026-06-30
-34.3%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $51.22M | -47.6% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $97.84M | -18.1% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $119.48M | -33.9% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $180.79M | +87.0% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $96.70M | n/a | 2023-03-22, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $51.22M | -47.6% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $15.99M | +70.3% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $32.35M | -18.2% |
| Creative Medical Technology Holdings, Inc. (CELZ) | 2025-12-31 | $7.81M | +17.1% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $5.78M | -32.8% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $7.39M | -49.6% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $1.64M | +195.7% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $93.00M | -4.0% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $61.88M | -36.3% |
Compare SNTI, ENTX, INMB, CELZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗